298 related articles for article (PubMed ID: 33202858)
1. Salivary Stress/Immunological Markers in Crohn's Disease and Ulcerative Colitis.
Finamore A; Peluso I; Cauli O
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202858
[TBL] [Abstract][Full Text] [Related]
2. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
Boon GJ; Day AS; Mulder CJ; Gearry RB
World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA signatures differentiate Crohn's disease from ulcerative colitis.
Schaefer JS; Attumi T; Opekun AR; Abraham B; Hou J; Shelby H; Graham DY; Streckfus C; Klein JR
BMC Immunol; 2015 Feb; 16():5. PubMed ID: 25886994
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
5. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review.
Gisbert JP; Chaparro M
J Crohns Colitis; 2019 Mar; 13(3):374-384. PubMed ID: 30307487
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn's Disease Patients with Different Disease Activity Using Video Capsule Endoscopy.
Fischer M; Siva S; Wo JM; Fadda HM
AAPS PharmSciTech; 2017 Feb; 18(2):404-409. PubMed ID: 27032935
[TBL] [Abstract][Full Text] [Related]
7. Proteomic insights on the metabolism in inflammatory bowel disease.
Pisani LF; Moriggi M; Gelfi C; Vecchi M; Pastorelli L
World J Gastroenterol; 2020 Feb; 26(7):696-705. PubMed ID: 32116417
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.
Kirsner JB
Dis Mon; 1991 Nov; 37(11):669-746. PubMed ID: 1935537
[TBL] [Abstract][Full Text] [Related]
9. Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission.
Palone F; Vitali R; Cucchiara S; Mennini M; Armuzzi A; Pugliese D; DʼIncà R; Barberio B; Stronati L
Inflamm Bowel Dis; 2016 Dec; 22(12):2886-2893. PubMed ID: 27755215
[TBL] [Abstract][Full Text] [Related]
10. Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease.
Williams AD; Korolkova OY; Sakwe AM; Geiger TM; James SD; Muldoon RL; Herline AJ; Goodwin JS; Izban MG; Washington MK; Smoot DT; Ballard BR; Gazouli M; M'Koma AE
PLoS One; 2017; 12(8):e0179710. PubMed ID: 28817680
[TBL] [Abstract][Full Text] [Related]
11. Challenges and Opportunities in IBD Clinical Trial Design.
Dubinsky MC; Collins R; Abreu MT;
Gastroenterology; 2021 Aug; 161(2):400-404. PubMed ID: 33864796
[No Abstract] [Full Text] [Related]
12. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis.
Bathe AL; Mavropoulou E; Mechie NC; Petzold G; Ellenrieder V; Kunsch S; Amanzada A
PLoS One; 2019; 14(10):e0223893. PubMed ID: 31647834
[TBL] [Abstract][Full Text] [Related]
13. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
[TBL] [Abstract][Full Text] [Related]
14. Micro-RNAs as regulators and possible diagnostic bio-markers in inflammatory bowel disease.
Archanioti P; Gazouli M; Theodoropoulos G; Vaiopoulou A; Nikiteas N
J Crohns Colitis; 2011 Dec; 5(6):520-4. PubMed ID: 22115369
[TBL] [Abstract][Full Text] [Related]
15. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory bowel disease. Part I: Nature and pathogenesis.
Kirsner JB
Dis Mon; 1991 Oct; 37(10):605-66. PubMed ID: 1893828
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing Inflammatory bowel disease using noninvasive applications of volatile organic compounds: a systematic review.
Bannaga AS; Farrugia A; Arasaradnam RP
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1113-1122. PubMed ID: 31657950
[No Abstract] [Full Text] [Related]
18. Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis.
Lehmann T; Schallert K; Vilchez-Vargas R; Benndorf D; Püttker S; Sydor S; Schulz C; Bechmann L; Canbay A; Heidrich B; Reichl U; Link A; Heyer R
J Proteomics; 2019 Jun; 201():93-103. PubMed ID: 31009805
[TBL] [Abstract][Full Text] [Related]
19. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
[TBL] [Abstract][Full Text] [Related]
20. Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.
Puolanne AM; Kolho KL; Alfthan H; Ristimäki A; Mustonen H; Färkkilä M
Dig Dis Sci; 2017 Nov; 62(11):3123-3130. PubMed ID: 28948412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
